Evidence map›Paper›PMID 40285809›Full record

SynthesisInvestigational new drugs2025

Glasdegib combined with chemotherapy in the treatment of patients with acute myeloid leukemia: a comprehensive meta-analysis.

Abdelaziz A Awad, Ahmed Yasser Shaban, Fatma Mohammed, Mohamed Mahmoud Marey, Mohamed A Aldemerdash, Ahmed W Abbas, Omar Saeed, Abdelrahman Saeed, Mahmoud M Elhady, Israa Sharabati and 4 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Abdelaziz A AwadFaculty of Medicine, Al-Azhar University, Cairo, Egypt. awad.abdelaziz.0505@gmail.com.
Ahmed Yasser ShabanFaculty of Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt.
Fatma MohammedFaculty of Medicine, Aswan University, Aswan, Egypt.
Mohamed Mahmoud MareyFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Mohamed A AldemerdashFaculty of Medicine, Sohag University, Sohag, Egypt.
Ahmed W AbbasFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Omar SaeedFaculty of Medicine, Al-Azhar University, Damietta, Egypt.
Abdelrahman SaeedFaculty of Medicine, Al-Azhar University, Damietta, Egypt.
Mahmoud M ElhadyFaculty of Medicine, Benha University, Qalubiya, Egypt.
Israa SharabatiDepartment of Pediatrics, Makassed Islamic Charitable Hospital, Jerusalem, Palestine.
Mohamed HamedFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Ahmed R A Abou-ShanabSchool of Health Sciences, Liberty University, Liberty, VA, USA.
Ahmed BahnasyHematology and Oncology Department, Medicine, Mayo Clinic, Scottsdale, AZ, USA.
Hussien Ahmed H AbdelgawadCenter for Cancer and Blood Disorders, Phoenix Children'S Hospital, Phoenix, AZ, USA. habdelgawad@phoenixchildrens.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) is characterized by clonal expansion of myeloid precursors, often accompanied by poor prognostic outcomes in older populations due to molecular heterogeneity and resistance to conventional chemotherapeutic agents. Glasdegib, a potent inhibitor of the Hedgehog signaling pathway, has emerged as a targeted agent that enhances chemosensitivity and demonstrates favorable pharmacodynamic profiles in combination regimens. This systematic review evaluates the clinical efficacy and safety of Glasdegib-based therapies in the management of AML.

methodsFollowing the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched four electronic databases (PubMed, Scopus, Cochrane Library, and Web of Science) to identify eligible studies reported up to August 2024. Using R version R.4.4.1, we reported outcomes as pooled proportions and confidence intervals (CIs). The survival data were extracted from Kaplan-Meier curves and reconstructed.

resultsThe pooled two-year overall survival for Glasdegib plus chemotherapy was 30% (95% CI [27-34%], I

conclusionGlasdegib combined with chemotherapy demonstrates promising efficacy in improving survival outcomes for AML patients, particularly in combination with Cytarabine and Daunorubicin. While adverse events were common, they were generally manageable, supporting Glasdegib as a viable therapeutic option. Further research is warranted to optimize treatment regimens and evaluate long-term safety and quality-of-life outcomes.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesLeukemia, Myeloid, AcutePhenylurea CompoundsCytarabineHumansAntineoplastic AgentsBenzimidazolesCytarabineglasdegibPhenylurea CompoundsAcute myeloid leukemiaChemotherapyGlasdegib

Identifiers

PMID40285809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.